Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Published:2023-01-26 Issue:4 Volume:388 Page:319-332
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Brown Jennifer R.¹,Eichhorst Barbara¹,Hillmen Peter¹,Jurczak Wojciech¹,Kaźmierczak Maciej¹,Lamanna Nicole¹,O’Brien Susan M.¹,Tam Constantine S.¹,Qiu Lugui¹,Zhou Keshu¹,Simkovic Martin¹,Mayer Jiri¹,Gillespie-Twardy Amanda¹,Ferrajoli Alessandra¹,Ganly Peter S.¹,Weinkove Robert¹,Grosicki Sebastian¹,Mital Andrzej¹,Robak Tadeusz¹,Osterborg Anders¹,Yimer Habte A.¹,Salmi Tommi¹,Wang Megan-Der-Yu¹,Fu Lina¹,Li Jessica¹,Wu Kenneth¹,Cohen Aileen¹,Shadman Mazyar¹

Affiliation:

1. From the Department of Medical Oncology, Dana–Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany (B.E.); St. James’s University Hospital, Leeds, United Kingdom (P.H.); Maria Skłodowska–Curie National Research Institute of Oncology, Krakow (W.J.), the Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan (M.K.), the Department of...

Funder

BeiGene

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2211582

Reference28 articles.

1. Cancer statistics, 2022

2. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

3. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy